Saxagliptin
- Generic Name
- Saxagliptin
- Brand Names
- Kombiglyze, Komboglyze, Onglyza, Qtern, Qternmet
- Drug Type
- Small Molecule
- Chemical Formula
- C18H25N3O2
- CAS Number
- 361442-04-8
- Unique Ingredient Identifier
- 8I7IO46IVQ
- Background
Saxagliptin (rINN) is an orally active hypoglycemic (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. FDA approved on July 31, 2009.
- Indication
Treatment of type 2 diabetes mellitus to improve glycemic control in combination with other agents or as monotherapy.
- Associated Conditions
- Type 2 Diabetes Mellitus
- Associated Therapies
- -
Harmonizing RCT-Duplicate Emulations In A Real World Replication Program (HARRP)
- First Posted Date
- 2023-10-25
- Last Posted Date
- 2023-10-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 239990
- Registration Number
- NCT06099067
- Locations
- 🇸🇪
Research Site, Gothenburg, Sweden
Cognitive Protective Effect of Newer Antidiabetic Drugs
- First Posted Date
- 2022-04-26
- Last Posted Date
- 2022-07-26
- Lead Sponsor
- Alexandria University
- Target Recruit Count
- 100
- Registration Number
- NCT05347459
- Locations
- 🇪🇬
Alexandria University, Alexandria, Egypt
Replication of the SAVOR-TIMI Diabetes Trial in Healthcare Claims
- First Posted Date
- 2019-05-03
- Last Posted Date
- 2023-08-01
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 182126
- Registration Number
- NCT03936023
- Locations
- 🇺🇸
Brigham & Women's Hospital, Boston, Massachusetts, United States
Study to Evaluate Safety and Efficacy of Dapagliflozin and Saxagliptin in Patients With Type 2 Diabetes Mellitus (T2DM) Aged 10 to Below 18 Years Old
- Conditions
- Interventions
- First Posted Date
- 2017-06-26
- Last Posted Date
- 2024-06-21
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 256
- Registration Number
- NCT03199053
- Locations
- 🇬🇧
Research Site, Nottingham, United Kingdom
Pre-diabetes in Subject With Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT)
- Conditions
- Interventions
- First Posted Date
- 2016-11-21
- Last Posted Date
- 2024-08-07
- Target Recruit Count
- 700
- Registration Number
- NCT02969798
- Locations
- 🇺🇸
The University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States
Study About Effect of Saxagliptin on Circulating Endothelial Progenitor Cells and Endothelial Function in Newly Diagnosed Type 2 Diabetic Patients
- First Posted Date
- 2016-09-30
- Last Posted Date
- 2016-10-03
- Lead Sponsor
- Shanghai Zhongshan Hospital
- Target Recruit Count
- 31
- Registration Number
- NCT02920801
- Locations
- 🇨🇳
Fang Li, Shanghai, Shanghai, China
Mechanistic Evaluation of Glucose-lowering Strategies in Patients With Heart Failure
- Conditions
- Interventions
- First Posted Date
- 2016-09-28
- Last Posted Date
- 2021-11-08
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 348
- Registration Number
- NCT02917031
- Locations
- 🇺🇦
Research Site, Rivne, Ukraine
A Single-dose Cross-over Study to Assess Direct and Indirect Effects of Dapagliflozin on Pancreatic Alpha and Beta Cells in Patients With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2016-05-06
- Last Posted Date
- 2016-12-12
- Lead Sponsor
- Uppsala University
- Target Recruit Count
- 15
- Registration Number
- NCT02765204
- Locations
- 🇸🇪
Dept of Medical Sciences Uppsala University Hospital, Uppsala, Sweden
Dipeptidyl Peptidase 4 Inhibition Facilitate Healing of Diabetic Ulcers
- First Posted Date
- 2016-04-18
- Last Posted Date
- 2017-08-08
- Lead Sponsor
- Long Min,MD
- Target Recruit Count
- 60
- Registration Number
- NCT02742233
- Locations
- 🇨🇳
The Second Affiliated Hospital, Third Military Medical University, Chongqing, Chongqing, China
A Multi-Center, Randomized, Double-Blind, Phase III Trial to Evaluate the Safety and Efficacy of Saxagliptin Co-administered With Dapagliflozin Compared to Saxagliptin or Dapagliflozin All Given as add-on Therapy to Metformin in Subject With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2016-02-12
- Last Posted Date
- 2018-10-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 905
- Registration Number
- NCT02681094
- Locations
- 🇷🇺
Research Site, Vladikavkaz, Russian Federation
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.